Clinical characteristics of patients with SBT
. | Patient no. 1 . | Patient no. 2 . | Patient no. 3 . | Patient no. 4 . |
|---|---|---|---|---|
| Time from CML diagnosis to start of imatinib, mo | 34.9 | 3.5 | 0.1 | 1.0 |
| Initial dose, mg/d | 400 | 400 | 800 | 800 |
| Pretreatment Sokal risk group | Low | Low | Low | Intermediate |
| Time to CGCR, mo | 6 | 3 | 6 | 3 |
| Best BCR-ABL/ABL ratio, % | 0 | 0.661 | 0.0012 | 0.8686 |
| Time from start of imatinib to BP, mo | 21 | 12 | 18 | 25 |
| Time from CGCR to BP, mo | 15.0 | 9 | 12 | 22 |
| Time from last bone marrow and cytogenetic analysis to BP, mo | 9 | 3 | 3 | 6 |
| BCR-ABL/ABL ratio immediately before BP, % | Undetectable | 0.661 | 65.5696 | 9.8737 |
| Blast phase morphology | Lymphoid | Myeloid | Lymphoid | Myeloid |
| Cytogenetics at time of BP | 45,xx,-8,t(9;22)(q34;q11.2), -20,+mar[1]; 46,XX[11] | 48,XX,+8,t(8;21)(q22;q22), t(9;22;19;10)(q34;q11.2; p13.1;q22),+der(22) t(9;22;19;10)[20] | 43-46,XY,-7,-8,I(9)(q10), t(9;22)(q34;q11.2),-13, -21,+der(22)t(9;22), +mar[13];46,XY[1] | 47,XY,t(3;21)(q26;q22),+8, t(9;22)(q34;q11.2)[17]; 46-48,XY, t(3;21) (q26;q22), +8,t(9;22)(q34;q11.2), +der(22)t(9;22)[3] |
| ABL mutations at time of BP | None | Not done | None | None |
| BCR-ABL/ABL ratio at time of BP, % | 19.8495 | 31.7167 | 65.5696 | 100 |
. | Patient no. 1 . | Patient no. 2 . | Patient no. 3 . | Patient no. 4 . |
|---|---|---|---|---|
| Time from CML diagnosis to start of imatinib, mo | 34.9 | 3.5 | 0.1 | 1.0 |
| Initial dose, mg/d | 400 | 400 | 800 | 800 |
| Pretreatment Sokal risk group | Low | Low | Low | Intermediate |
| Time to CGCR, mo | 6 | 3 | 6 | 3 |
| Best BCR-ABL/ABL ratio, % | 0 | 0.661 | 0.0012 | 0.8686 |
| Time from start of imatinib to BP, mo | 21 | 12 | 18 | 25 |
| Time from CGCR to BP, mo | 15.0 | 9 | 12 | 22 |
| Time from last bone marrow and cytogenetic analysis to BP, mo | 9 | 3 | 3 | 6 |
| BCR-ABL/ABL ratio immediately before BP, % | Undetectable | 0.661 | 65.5696 | 9.8737 |
| Blast phase morphology | Lymphoid | Myeloid | Lymphoid | Myeloid |
| Cytogenetics at time of BP | 45,xx,-8,t(9;22)(q34;q11.2), -20,+mar[1]; 46,XX[11] | 48,XX,+8,t(8;21)(q22;q22), t(9;22;19;10)(q34;q11.2; p13.1;q22),+der(22) t(9;22;19;10)[20] | 43-46,XY,-7,-8,I(9)(q10), t(9;22)(q34;q11.2),-13, -21,+der(22)t(9;22), +mar[13];46,XY[1] | 47,XY,t(3;21)(q26;q22),+8, t(9;22)(q34;q11.2)[17]; 46-48,XY, t(3;21) (q26;q22), +8,t(9;22)(q34;q11.2), +der(22)t(9;22)[3] |
| ABL mutations at time of BP | None | Not done | None | None |
| BCR-ABL/ABL ratio at time of BP, % | 19.8495 | 31.7167 | 65.5696 | 100 |
BP indicates blast phase.